Pathology: squamous - mNSCLC - L1 - all population;
| squamous - mNSCLC - L1 - all population | ||||
| IMpower-131 (ACnP), 2020 | IMpower-131 (ACP) EXPLORATORY, 2020 | KEYNOTE-407, 2018 | ||
| atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | ||
| atezolizumab plus carboplatin plus paclitaxel | 1 | T1 | ||
| pembrolizumab plus SoC | 1 | T1 | ||
| carboplatin plus nab-paclitaxel | 0 | T0 | ||
| nab-paclitaxel | 0 | T0 | ||
| placebo plus SoC | 0 | T0 | ||